HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Chakraborty, A. Articles by Cheung, W. Search for Related Content PubMed PubMed Citation Articles by Chakraborty, A. Articles by Cheung, W. Social Bookmarking                         What's this?

Population Pharmacokinetics of Erythropoietin in Critically Ill Subjects

From Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey.

The effects of various covariate factors on the pharmacokinetics of erythropoietin (EPO) in subjects who are critically ill and admitted to an intensive care unit were evaluated. Nonlinear mixed-effects modeling was used to analyze the data from 48 patients receiving subcutaneous doses of 40 000 IU/wk epoetin alfa enrolled in a randomized, double-blind, placebo-controlled, multicenter study. The pharmacokinetics of EPO follows a 1-compartment disposition model with first-order absorption and an endogenous input rate. For a patient weighing 70 kg, the typical apparent clearance (CL/F) and apparent volume of distribution (V/F) were estimated to be 1.86 L/h and 27.8 L. The interindividual variability in CL/F and V/F was estimated to be 57.2% and 83.8%. CL/F and V/F of EPO increased with body weight, as described by the following relation: CL/F = (CL/F)_std*(W/W_std)^0.75, and V/F = (V/F)_std*(W/W_std)^1.37, where W is individual weight, and W_std is the median weight of the study population. There was a 46% drop in exposure of EPO from the first to the subsequent dosing events. The endogenous EPO production rate was found to decrease progressively with the course of the study. In addition, the modeled endogenous EPO production rate increased with body weight. The net effect of this increase on the endogenous plasma EPO levels may not be significant because EPO clearance was found to increase with body weight. All other factors investigated (eg, Sequential Organ Failure Assessment [SOFA] scores and APACHE II scores) had no significant effect on EPO pharmacokinetics. The typical population estimate of CL/F of EPO was close to previously reported values in healthy volunteers.

Key Words: Critically ill • erythropoietin (EPO) • pharmacokinetics • population model

Address for reprints: Abhijit Chakraborty, PhD, Advanced PK/PD Modeling & Simulation Department, Global Clinical Pharmacokinetics & Clinical Pharmacology Division, Johnson & Johnson Pharmaceutical Research & Development, LLC, 920 Route 202 South, Raritan, NJ 08869.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Zarychanski MD, A. F. Turgeon MD MSc, L. McIntyre MD MHSc, and D. A. Fergusson MHA PhD Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials Can. Med. Assoc. J., September 25, 2007; 177(7): 725 - 734. [Abstract] [Full Text] [PDF]

				S. S. Srouji, Y. L. Pagan, F. D'Amato, A. Dabela, Y. Jimenez, J. G. Supko, and J. E. Hall Pharmacokinetic Factors Contribute to the Inverse Relationship between Luteinizing Hormone and Body Mass Index in Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1347 - 1352. [Abstract] [Full Text] [PDF]